Back to Browse Journals » Biologics: Targets and Therapy » Volume 3

HER2 breast cancer therapies: a review

Authors Conleth G Murphy, Shanu Modi

Published Date June 2009 Volume 2009:3 Pages 289—301

DOI http://dx.doi.org/10.2147/BTT.S3479

Published 11 June 2009

Conleth G Murphy, Shanu Modi

Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Abstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer outcomes compared to ‘HER2 normal’ breast cancer. Research has focused on developing therapies directed to the HER2 receptor and its pathway. These include the monoclonal antibody trastuzumab, which has improved outcomes when used in patients with both advanced and early breast cancer. Lapatinib is a small-molecule tyrosine kinase inhibitor which has demonstrated activity in advanced breast cancer and is currently being evaluated in early stage disease. We discuss the therapeutic rationale and clinical trial experience with these agents. Other novel and emerging strategies targeting the HER2 receptor and its pathway are also discussed. These strategies include novel HER2 antibodies and small-molecule inhibitors, antibody–drug conjugates, agents targeting downstream components of the HER2 signaling pathway, and heat shock protein 90 (HSP90) inhibitors.

Keywords: HER2, human epidermal growth factor receptor 2, breast cancer, trastuzumab, lapatinib

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Ganetespib: research and clinical development

Jhaveri K, Modi S

OncoTargets and Therapy 2015, 8:1849-1858

Published Date: 24 July 2015

Readers of this article also read:

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]

Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C

Clinical Pharmacology: Advances and Applications 2014, 6:61-62

Published Date: 27 March 2014

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo

Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL

International Journal of Nanomedicine 2013, 8:4103-4114

Published Date: 30 October 2013

Glaucoma associated with the management of rhegmatogenous retinal detachment

Mangouritsas G, Mourtzoukos S, Portaliou DM, Georgopoulos VI, Dimopoulou A, Feretis E

Clinical Ophthalmology 2013, 7:727-734

Published Date: 15 April 2013

Gefarnate stimulates mucin-like glycoprotein secretion in conjunctival tissue and ameliorates corneal epithelial damage in animal dry-eye models

Dota A, Takaoka-Shichijo Y, Nakamura M

Clinical Ophthalmology 2013, 7:211-217

Published Date: 29 January 2013

The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model

Christoforidis J, Ricketts R, Pratt C, Pierce J, Bean S, Wells M, Zhang X, La Perle K

Clinical Ophthalmology 2012, 6:61-69

Published Date: 10 January 2012

Corrigendum

Sudenga SL, Royse KE, Shrestha S

Adolescent Health, Medicine and Therapeutics 2011, 2:95-96

Published Date: 15 September 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010